Three-program alliance with Synaffix reflects SOTIO’s commitment to further broaden and advance innovative ADC pipeline PRAGUE & AMSTERDAM--(BUSINESS WIRE)-- SOTIO Biotech, a clinical-stage ...

CEO Abizer Gaslightwala discusses the Company’s recent announcement around its ADC pipeline expansion and IP strategyCompany also discusses its ...

-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin ...

(RTTNews) - Next Cure Inc. (NXTC) outlined steady clinical and operational momentum across its two antibody-drug conjugate programs while reporting a preliminary year-end cash position that supports ...

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- ...

Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all ...

USD 361 million round represents the largest Series C for a European biotechnology company and the largest financing for a private ADC developer globally Round led by Venrock Healthcare Capital ...

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded BioNTech SE (NASDAQ:BNTX) from Neutral to Buy and boosted its price target from ...

PRAGUE & AMSTERDAM--(BUSINESS WIRE)--SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, today announced it will be exercising its option, under its license and option ...